candesartan cilexetil has been researched along with Diabetic Glomerulosclerosis in 8 studies
candesartan cilexetil: a prodrug which is metabolized to an active form candesartan to exert its biological effects
| Excerpt | Relevance | Reference |
|---|---|---|
| "The effect of the angiotensin II receptor blocker, candesartan cilexetil, on proteinuria was examined in a prospective, multicenter, randomized, double-blind study in Japanese subjects with type 2 diabetes." | 5.11 | Antiproteinuric effect of candesartan cilexetil in Japanese subjects with type 2 diabetes and nephropathy. ( Haneda, M; Kawamori, R; Kikkawa, R; Sakai, H, 2004) |
| "Fifty-two patients with type 2 diabetes with normo- and microalbuminuria participated in this study." | 2.71 | Low-dose candesartan cilexetil prevents early kidney damage in type 2 diabetic patients with mildly elevated blood pressure. ( Adachi, M; Hirano, T; Ikejiri, R; Murayama, S; Okada, K; Sakaue, T, 2003) |
| "Many patients with diabetic nephropathy (DN) have levels of albuminuria > 1 g/day and blood pressure >135/85 mmHg, despite antihypertensive combination therapy, including recommended doses of ACE inhibitors, e." | 2.70 | Dual blockade of the renin-angiotensin system in diabetic nephropathy: a randomized double-blind crossover study. ( Christensen, PK; Jensen, BR; Parving, HH; Rossing, K, 2002) |
| "It was launched in 1998 for the treatment of hypertension." | 2.45 | Candesartan: widening indications for this angiotensin II receptor blocker? ( Mendis, B; Page, SR, 2009) |
| "Many models of diabetic nephropathy have been reported." | 1.38 | A novel diabetes mellitus mouse model, MAFA-deficient and beta cell-specific MAFK-overexpressing hybrid transgenic mice, developed severe diabetic nephropathy and improved with TCV-116 (candesartan cilexetil) treatment. ( Fujita, A; Morito, N; Ojima, M; Okamura, M; Shimohata, H; Takahashi, S; Yamagata, K; Yoh, K, 2012) |
| "The pregnancy was terminated, and she delivered at 27 weeks' gestation." | 1.35 | Oligohydramnios and pulmonary hypoplasia: a case in which involvement of an angiotensin II receptor antagonist was suspected. ( Hirahara, F; Ishikawa, H; Kato, K; Okuda, M; Takahashi, T, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (87.50) | 29.6817 |
| 2010's | 1 (12.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Mendis, B | 1 |
| Page, SR | 1 |
| Fujita, A | 1 |
| Yoh, K | 1 |
| Shimohata, H | 1 |
| Morito, N | 1 |
| Ojima, M | 1 |
| Okamura, M | 1 |
| Takahashi, S | 1 |
| Yamagata, K | 1 |
| Murayama, S | 1 |
| Hirano, T | 1 |
| Sakaue, T | 1 |
| Okada, K | 1 |
| Ikejiri, R | 1 |
| Adachi, M | 1 |
| Kakizawa, H | 1 |
| Itoh, Y | 1 |
| Imamura, S | 1 |
| Matsumoto, T | 1 |
| Ishiwata, Y | 1 |
| Ono, Y | 1 |
| Yamamoto, K | 1 |
| Kato, T | 1 |
| Hayakawa, N | 1 |
| Oda, N | 1 |
| Goto, Y | 2 |
| Nagasaka, A | 1 |
| Senda, T | 1 |
| Itoh, M | 1 |
| Haneda, M | 1 |
| Kikkawa, R | 1 |
| Sakai, H | 1 |
| Kawamori, R | 1 |
| Kato, K | 1 |
| Okuda, M | 1 |
| Ishikawa, H | 1 |
| Takahashi, T | 1 |
| Hirahara, F | 1 |
| Nakamura, T | 1 |
| Ushiyama, C | 1 |
| Suzuki, S | 1 |
| Shimada, N | 1 |
| Sekizuka, K | 1 |
| Ebihara, I | 1 |
| Takahashi, Y | 1 |
| Tanaka, A | 1 |
| Koide, H | 1 |
| Rossing, K | 1 |
| Christensen, PK | 1 |
| Jensen, BR | 1 |
| Parving, HH | 1 |
1 review available for candesartan cilexetil and Diabetic Glomerulosclerosis
| Article | Year |
|---|---|
Candesartan: widening indications for this angiotensin II receptor blocker?
Topics: Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Cardiovascular Diseases | 2009 |
4 trials available for candesartan cilexetil and Diabetic Glomerulosclerosis
| Article | Year |
|---|---|
Low-dose candesartan cilexetil prevents early kidney damage in type 2 diabetic patients with mildly elevated blood pressure.
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Biphe | 2003 |
Antiproteinuric effect of candesartan cilexetil in Japanese subjects with type 2 diabetes and nephropathy.
Topics: Angiotensin Receptor Antagonists; Benzimidazoles; Biphenyl Compounds; Creatinine; Diabetes Mellitus, | 2004 |
Comparison between the angiotensin II receptor antagonist candesartan cilexetil and the angiotensin-converting enzyme inhibitor trandolapril in microalbuminuria of patients with early diabetic nephropathy.
Topics: Albuminuria; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihyperte | 2000 |
Dual blockade of the renin-angiotensin system in diabetic nephropathy: a randomized double-blind crossover study.
Topics: Adrenergic beta-Antagonists; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 2002 |
3 other studies available for candesartan cilexetil and Diabetic Glomerulosclerosis
| Article | Year |
|---|---|
A novel diabetes mellitus mouse model, MAFA-deficient and beta cell-specific MAFK-overexpressing hybrid transgenic mice, developed severe diabetic nephropathy and improved with TCV-116 (candesartan cilexetil) treatment.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphe | 2012 |
Possible role of VEGF in the progression of kidney disease in streptozotocin (STZ)-induced diabetic rats: effects of an ACE inhibitor and an angiotensin II receptor antagonist.
Topics: Albuminuria; Analysis of Variance; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme I | 2004 |
Oligohydramnios and pulmonary hypoplasia: a case in which involvement of an angiotensin II receptor antagonist was suspected.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Diabetic Nephrop | 2008 |